Ohio flu hospitalizations doubled in last week of 2025

Ohio reported flu hospitalizations rose to 1,465 in the week ending Dec. 27, up from 745 the prior week and well above the historical average of 665 for that week, as a new flu variant spreads across the U.S. The surge, part of a nationwide wave driving millions of infections, raises near-term pressure on healthcare utilization and could modestly disrupt regional consumer activity and workforce availability, though it is unlikely to be a major market-moving event.

Analysis

Market structure: Rapid doubling in Ohio hospitalizations (1,465 vs historical 665 for week ending Dec. 27) signals near-term surge in demand for diagnostics, rapid tests, OTC symptom relief, urgent care and antivirals while elective procedures and insurer margins come under pressure. Winners: diagnostics (rapid-test makers, lab suppliers), retail pharmacies/urgent care (CVS, WBA), selected vaccine/antiviral manufacturers (PFE, SNY/GSK) for medium-term product demand. Losers: elective-care reliant hospitals, short-term margin pressure for insurers (UNH, CI) from higher claim frequency; pricing power for vaccines is limited by government purchasing but testing volumes can drive meaningful revenue bumps for 4–12 weeks.

Risk assessment: Tail risks include a vaccine-escape variant or multi-month wave leading to government price controls, export restrictions on antivirals, or staffing shortages that materially hit hospital operator earnings — low probability but high impact over 1–6 months. Near-term (days–weeks) risk is seasonal volatility and noisy data; short-term catalysts are CDC weekly ILI reports, state hospitalization releases, and FDA emergency authorizations; longer-term (quarters) risk is normalization and rapid demand drop-off once season passes. Hidden dependencies: insurer reimbursement lag, inventory replenishment cycles, and school/workplace closure policies that can amplify or truncate demand within 2–8 weeks.

Trade implications: Favor high-conviction, time-limited exposure to diagnostics and lab suppliers (QDEL, ABT, TMO) via call spreads or small equity stakes for 4–12 week windows; reduce directional exposure to insurers/hospital operators or buy protection given potential QoQ EPS drag. Use pair trades (long QDEL/ABT, short UNH/HCA) to isolate testing volume vs structural healthcare exposure. Options strategies: buy 4–8 week call spreads on testing names and buy 3–6 month protective puts on insurers; size intraday/weekly entries to manage rapid information flow and exit on hospitalization decline to <900 in Ohio or national ILI back to historical average.

Contrarian angles: Consensus often overweights large vaccine names (MRNA, PFE) for revenue; near-term mispricing is in testing and OTC players where weeks of elevated volume can translate to +20–50% revenue shocks. Historical parallel: severe 2017–18 flu produced 4–10 week spikes in testing/OTC sales and outsized quarterly beats for diagnostics/retail pharmacies. Beware unintended consequences: aggressive shorting of insurers could be punished by delayed recognition of claims or government interventions; therefore prefer hedged pair trades and clearly defined stop-loss thresholds.

Key Decisions for Investors

• Establish a 2–3% long position in QuidelOrtho (QDEL) via a 6–8 week call spread (buy near-ATM, sell 20–25% OTM) within the next 5 trading days; target asymmetric upside of 25–50% if testing volumes remain elevated, stop-loss if spread premium falls >50% from entry.
• Buy a 1.5–2% equity or 2-month ATM call position in Abbott Laboratories (ABT) to capture rapid-test and point-of-care volume; exit on sequential weekly testing volume decline or when Ohio hospitalizations drop below 900 (statewide) or national ILI returns to historical mean.
• Initiate a 1–2% long in Thermo Fisher (TMO) via a 3-month call spread to play lab-supply demand; close position if order flows/inventory builds indicate >30% restocking or if hospital staffing shortages push utilization below seasonal norms.
• Hedge downside in insurers: buy a 3-month 5–7% OTM put on UnitedHealth (UNH) sized ~1% portfolio risk or shift 1–2% short exposure to UNH/HCA as a pair with long diagnostic names to protect against QoQ earnings misses driven by higher claims.
• Rotate 2% from cyclical discretionary into CVS Health (CVS) or Walgreens (WBA) long exposure (equity or 3-month call) to capture OTC and urgent-care revenue; trim if same-store sales growth reverts to seasonally adjusted historical levels or after 90 days.